A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT06188559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2) Antibody-drug Conjugate (ADC), in Previously Treated Subjects With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer (BC).
Study identification
- NCT ID
- NCT06188559
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2024 (Actual)
- Primary completion
- Mar 18, 2026 (Actual)
- Completion
- Mar 18, 2026 (Actual)
- Last update posted
- May 22, 2026
2024 – 2026
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| UCLA Center for East-West Medicine | Los Angeles | California | 90095 | — |
| UCSF | San Francisco | California | 94143-2208 | — |
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | — |
| AdventHealth Cancer Institute - Orlando | Orlando | Florida | 32804 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612-9416 | — |
| Fort Wayne Medical Oncology & Hematology | Fort Wayne | Indiana | 48604 | — |
| Community Cancer Center South | Indianapolis | Indiana | 46227 | — |
| Mission Blood and Cancer | Des Moines | Iowa | 50309 | — |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109-5000 | — |
| Washington University in St. Louis School of Medicine | St Louis | Missouri | 63110-1032 | — |
| NHO Revive Research Institute LLC | Lincoln | Nebraska | 68506 | — |
| Nebraska Cancer Specialist | Omaha | Nebraska | 68130-2042 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| Summit Medical Group | Florham Park | New Jersey | 07932-1049 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| New Mexico Oncology Hematology Consultants | Albuquerque | New Mexico | 87109 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center) | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center | Cleveland | Ohio | 44124 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195-0001 | — |
| Oregon Oncology Specialists | Salem | Oregon | 97301 | — |
| UPMC CancerCenter at Magee - Womens Hospital | Pittsburgh | Pennsylvania | 15213-3108 | — |
| St. Francis Cancer Center | Greenville | South Carolina | 29607-5253 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| The West Clinic, PLLC dba West Cancer Cente | Germantown | Tennessee | 38138-1762 | — |
| Northwest Medical Specialties | Puyallup | Washington | 98373-1428 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06188559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 22, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06188559 live on ClinicalTrials.gov.